Small Pharma has announced results from its Phase 2a trial of its intravenous formulation of DMT – SPL026 – demonstrating improvement in depression and anxiety.
Using machine learning analysis, researchers have determined that a mystical and insightful psychedelic drug experience may be linked to long-term reductions in anxiety and depression symptoms.
Awakn Life Sciences has signed its first Licensing Partnership agreement in Europe with a healthcare consortium.
In what marks a significant finding in the advancement of psychedelic research, a new study has demonstrated that the location of serotonin 2A receptors (5-HT2A) is...
LongeVC has invested in psychedelics startup Freedom Biosciences which is pioneering the use of ketamine and other compounds in next-generation treatments.
Tadeusz Hawrot, Founder and Executive Director of the Psychedelic Access and Research European Alliance (PAREA), speaks to Psychedelic Health about how the organisation plans to campaign...
Peter Reitano, CEO of Gwella, speaks to Psychedelic Health about the company’s mission to provide education on psychedelics and raise acceptance of the compounds beyond mental...
Incannex Healthcare has confirmed that its PsiGAD1 clinical trial has achieved its interim milestone of 29 patients completing primary endpoint assessments.
Biopharmaceutical company Cybin has selected generalised anxiety disorder (GAD), with or without major depressive disorder (MDD), as the target indication for its proprietary deuterated DMT molecule,...
Irwin Naturals has signed a Letter of Intent entering into a partnership with Braxia Scientific – which is developing innovative ketamine and psilocybin treatments for mental...